Rein Therapeutics, Inc.
RNTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.58
KIRA · Stoqly’s AI analyst, in plain words
- Rein Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Rein Therapeutics, Inc. lost $49.9M in fiscal 2025.
Market cap
$39.1M
P/E
—
Revenue
$0.0M
Net income
−$49.9M
Free cash flow
—
Operating margin
—
Rein Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$49.9M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Rein Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Rein Therapeutics, Inc.
- CIK
- 0001420565
Rein Therapeutics, Inc. · RNTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | −$26.2M | −$27.3M | −$15.7M | −$62.9M | −$49.9M |
| Diluted EPS | −$5.89 | −$6.02 | −$3.42 | −$3.51 | −$1.96 |
| Cash | |||||
| Cash from operations | −$23.8M | −$24.9M | −$19.8M | −$22.3M | −$19.4M |
| Capital expenditure | $0.2M | — | — | — | — |
| Free cash flow | −$23.9M | — | — | — | — |
| Share count change | −87.3% | 2.2% | 1.3% | 290.1% | 41.8% |
| Debt and strength | |||||
| Cash and short-term investments | $45.9M | $21.2M | $17.3M | $12.9M | $3.2M |
| Shareholders' equity | $43.9M | $18.6M | $98.3M | $54.4M | $16.9M |
| Current ratio | 10.7x | 6.5x | 4.2x | 2.4x | 0.7x |
| Returns and quality | |||||
| Return on equity | −93.3% | −87.4% | −26.9% | −82.4% | −139.9% |
| Return on tangible equity | −59.6% | −146.7% | −123.2% | −1,072.7% | — |
| Piotroski F-score | 4 | 1 | 1 | 1 | 1 |
| Altman Z'' | −4.2 | −37.6 | 4.3 | −17.3 | −66.3 |
Insiders bought, 12 months
$0.4M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Rein Therapeutics, Inc. · RNTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.58 a share, the company is worth $39.1M.
Source: SEC EDGAR XBRL filings (CIK 0001420565). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.